A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+metastatic breast cancer (MBC)

被引：0

作者：

Borges, Virginia F. ^{[1
]}

Hamilton, Erika ^{[2
,3
]}

Yardley, Denise A. ^{[2
,3
]}

Chaves, Jorge ^{[4
]}

Aucoin, Nathalie ^{[5
]}

Ferrario, Cristiano ^{[6
]}

Walker, Luke ^{[7
]}

Krop, Ian ^{[8
]}

机构：

[1] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Tennessee Oncol PLLC, Nashville, TN USA

[4] Northwest Med Specialties, Tacoma, WA USA

[5] Hop Cite de la Sante, Laval, PQ, Canada

[6] Jewish Gen Hosp, Montreal, PQ, Canada

[7] Oncothyreon Inc, Seattle, WA USA

[8] Dana Farber Canc Inst, Boston, MA USA

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P4-15-08

引用

页数：2

共 50 条

[1] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with adotrastuzumab emtansine (T-DM1), in HER2+metastatic breast cancer (MBC)
Borges, Virginia F.
Hamilton, Erika Paige
Yardley, Denise A.
Moulder, Stacy L.
Hortobagyi, Gabriel N.
Walker, Luke N.
Krop, Ian E.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[2] A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+metastatic breast cancer (MBC)
Ferrario, C.
Hamilton, E.
Aucoin, N.
Falkson, C. L.
Khan, Q.
Krop, I. E.
Welch, S.
Bedard, P. L.
Conlin, A.
Chaves, J.
Vo, A.
Walker, L.
Borges, V.
CANCER RESEARCH, 2016, 76
[3] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and trastuzumab, in HER2+metastatic breast cancer (MBC)
Hamilton, Erika Paige
Yardley, Denise A.
Hortobagyi, Gabriel N.
Walker, Luke N.
Borges, Virginia F.
Moulder, Stacy L.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and/or trastuzumab, in HER2+metastatic breast cancer (MBC)
Hamilton, Erika
Yardley, Denise A.
Hortobagyi, Gabriel
Walker, Luke
Borges, Virginia F.
Moulder, Stacy
CANCER RESEARCH, 2015, 75
[5] Phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line plus treatment of HER2+metastatic breast cancer (MBC).
Hamilton, Erika Paige
Yardley, Denise A.
Hortobagyi, Gabriel N.
Walker, Luke N.
Borges, Virginia F.
Moulder, Stacy L.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[6] Efficacy results of a phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in HER2+metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets)
Hamilton, E.
Borges, V.
Conlin, A.
Walker, L.
Moulder, S.
CANCER RESEARCH, 2017, 77
[7] Cutaneous responses in Her-2+metastatic breast cancer (MBC) on phase 1b study of ONT-380, an oral HER2-specific in combination with capecitabine (C) and/or trastuzumab (T) in third line or later treatment
Conlin, A. K.
Borges, V. F.
Moxon, N. M.
Walker, L. N.
Moulder, S. L.
ANNALS OF ONCOLOGY, 2016, 27
[8] A phase 1b study of S-1 combined with trastuzumab emtansine (T-DM1) for HER2 positive metastatic breast cancer
Kojima, Yasuyuki
Yoshie, Reiko
Kawamoto, Hisanori
Shimo, Arata
Uejima, Tomoko
Iwatani, Tsuguo
Motoyoshi, Ai
Haku, Ei
Kanemaki, Yoshihide
Tsugawa, Koichiro
ANNALS OF ONCOLOGY, 2018, 29
[9] Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
Spring, Laura M.
Clark, Shealagh L.
Li, Tianyu
Goel, Shom
Tayob, Nabihah
Viscosi, Elene
Abraham, Elizabeth
Juric, Dejan
Isakoff, Steven J.
Mayer, Erica
Moy, Beverly
Supko, Jeffrey G.
Tolaney, Sara M.
Bardia, Aditya
NPJ BREAST CANCER, 2021, 7 (01)
[10] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
Ian E. Krop
Shanu Modi
Patricia M. LoRusso
Mark Pegram
Ellie Guardino
Betsy Althaus
Dan Lu
Alexander Strasak
Anthony Elias
Breast Cancer Research, 18

← 1 2 3 4 5 →